Current Urology Reports

, 16:4 | Cite as

Percutaneous Tibial Nerve Stimulation and Sacral Neuromodulation: an Update

  • Priyanka Gupta
  • Michael J. Ehlert
  • Larry T. Sirls
  • Kenneth M. PetersEmail author
Female Urology (K Kobashi, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Female Urology


Neuromodulation is an important treatment modality for a variety of pelvic floor disorders. Percutaneous tibial nerve stimulation (PTNS) and sacral neuromodulation (SNM) are currently the two approved methods for delivering this therapy. Percutaneous tibial nerve stimulation is a minimally invasive office-based procedure that has shown efficacy in the treatment of overactive bladder, fecal incontinence, and pelvic pain. It has the advantage of minimal side effects but is limited by the need for patients to make weekly office visits to receive the series of treatments. Sacral neuromodulation uses an implanted device that stimulates the S3 nerve root and can improve symptoms of overactive bladder, non-obstructive urinary retention, fecal incontinence, and pelvic pain. This paper will review the most recent literature regarding this topic and discuss their advantages and limitations and recent innovations in their use.


Neuromodulation Percutaneous tibial nerve stimulation Sacral neuromodulation InterStim® Overactive bladder Urgency urinary incontinence 



Percutaneous tibial nerve stimulation


Overactive bladder


Sacral neuromodulation


Urgency urinary incontinence


Fecal incontinence


Compliance with Ethics Guidelines

Conflict of Interest

Dr. Priyanka Gupta, Dr. Michael J. Ehlert, and Dr. Larry T. Sirls each declare no potential conflicts of interest.

Dr. Kenneth M. Peters declares personal fees from Medtronic and Uroplasty.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Wu JM, Vaughan CP, Goode PS, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014;123(1):141–8.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.PubMedGoogle Scholar
  3. 3.
    Schlenk EA, Erlen JA, Dunbar-Jacob J, et al. Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res. 1998;7(1):57–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008;112(6):1311–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009;15(4 Suppl):S118–22.PubMedGoogle Scholar
  6. 6.
    Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. The Journal of urology. Dec. 188(6 Suppl):2455–2463.Google Scholar
  7. 7.
    Tanagho EA, Schmidt RA, Orvis BR. Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol. 1989;142(2 Pt 1):340–5.PubMedGoogle Scholar
  8. 8.
    Hasan ST, Robson WA, Pridie AK, Neal DE. Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability. J Urol. 1996;155(6):2005–11.CrossRefPubMedGoogle Scholar
  9. 9.
    Cooperberg MR, Stoller ML. Percutaneous neuromodulation. Urologic Clin North Am. 2005;32(1):71–8.CrossRefGoogle Scholar
  10. 10.
    Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–6.CrossRefPubMedGoogle Scholar
  12. 12.
    van Balken MR, Vandoninck V, Gisolf KW, et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol. 2001;166(3):914–8.CrossRefPubMedGoogle Scholar
  13. 13.••
    Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61. This randomized control trial showed significant improvement in overactive bladder symptoms with PTNS (79.5%) compared to 54.8% of tolterodine subjects on the global response assessment. Objective measures of frequency, urgency, and nighttime voids showed comparable effectiveness between PTNS and pharmacotherapy.CrossRefPubMedGoogle Scholar
  14. 14.
    Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Invest. 2013;75(4):230–4.CrossRefPubMedGoogle Scholar
  15. 15.••
    Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. The Journal of urology. Jun; 189(6):2194-2201. In this prospective study patients were followed for 36 months and received a 14-week tapering protocol for PTNS treatments. They found that an average of 1.1 treatments per month were required for continued treatment of OAB. Google Scholar
  16. 16.
    MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183(1):234–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Maurelli V, Petta F, Carsillo G, et al. What to do if percutaneous tibial nerve stimulation (PTNS) works? A pilot study on home-based transcutaneous tibial nerve stimulation. Urologia. 2012;79(19):86–90.PubMedGoogle Scholar
  18. 18.
    Chen HW, Bercik RS, Werner EF, Thung SF. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. J Urol. 2012;187(1):178–84.CrossRefPubMedGoogle Scholar
  19. 19.
    Horrocks EJ, Thin N, Thaha MA, Taylor SJ, Norton C, Knowles CH. Systematic review of tibial nerve stimulation to treat faecal incontinence. Br J Surg. 2014;101(5):457–68.CrossRefPubMedGoogle Scholar
  20. 20.
    Kabay S, Kabay SC, Yucel M, Ozden H. Efficiency of posterior tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain: a Sham-controlled comparative study. Urol Int. 2009;83(1):33–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Leong RK, De Wachter SG, Nieman FH, de Bie RA, van Kerrebroeck PE. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy. Neurourol Urodyn. 2011;30(7):1249–52.PubMedGoogle Scholar
  22. 22.
    Kantartzis KL, Shepherd JP. Cost-effectiveness of test phase implantation strategies for InterStim(R) sacral neuromodulation. Female Pelvic Med Reconstr Surg. 2013;19(6):322–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Marcelissen TA, Leong RK, de Bie RA, van Kerrebroeck PE, de Wachter SG. Long-term results of sacral neuromodulation with the tined lead procedure. J Urol. 2010;184(5):1997–2000.CrossRefPubMedGoogle Scholar
  24. 24.
    van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178(5):2029–34.CrossRefPubMedGoogle Scholar
  25. 25.
    Sutherland SE, Lavers A, Carlson A, Holtz C, Kesha J, Siegel SW. Sacral nerve stimulation for voiding dysfunction: one institution’s 11-year experience. Neurourol Urodyn. 2007;26(1):19–28. discussion 36.CrossRefPubMedGoogle Scholar
  26. 26.•
    Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourology and urodynamics. Jan 10 2014. In this randomized conrolled trial sacral neuromodulation had statistically significant greater therapeutic success compared to standard medical therapy in the intent to treat analysis (61 versus 42 %). It also demonstrated superior subjective success for treatment of OAB symptoms. Google Scholar
  27. 27.
    Anger JT, Cameron AP, Madison R, Saigal CS, Clemens JQ. The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population. Neuromodulation. 2014;17(1):72–4. discussion 74.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Peeters K, Sahai A, De Ridder D, Van Der Aa F. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014;113(5):789–94.CrossRefPubMedGoogle Scholar
  29. 29.
    Gross C, Habli M, Lindsell C, South M. Sacral neuromodulation for nonobstructive urinary retention: a meta-analysis. Female Pelvic Med Reconstr Surg. 2010;16(4):249–53.CrossRefPubMedGoogle Scholar
  30. 30.•
    McNevin MS, Moore M, Bax T. Outcomes associated with Interstim therapy for medically refractory fecal incontinence. Am J Surg. 2014;207(5):735–37. In this retrospective study over a 2-year time period patients with fecal incontinence refractory to standard medical treatment demonstrtated an improvement in number of episodes of fecal incontinence. Number of accidents decreased on average from 19 every 2 weeks to 3 accidents after device implantation.CrossRefPubMedGoogle Scholar
  31. 31.
    Devroede G, Giese C, Wexner SD, et al. Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation. Female Pelvic Med Reconstr Surg. 2012;18(2):103–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Marcelissen T, Jacobs R, van Kerrebroeck P, de Wachter S. Sacral neuromodulation as a treatment for chronic pelvic pain. J Urol. 2011;186(2):387–93.CrossRefPubMedGoogle Scholar
  33. 33.
    Dwyer ME, Vandersteen DR, Hollatz P, Reinberg YE. Sacral Neuromodulation for the Dysfunctional Elimination Syndrome: A 10-Year Single-center Experience With 105 Consecutive Children. Urology. Aug 2 2014.Google Scholar
  34. 34.
    Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189(1):210–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Siddiqui NY, Wu JM, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol Urodyn. 2010;29 Suppl 1:S18–23.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Priyanka Gupta
    • 1
  • Michael J. Ehlert
    • 1
  • Larry T. Sirls
    • 2
  • Kenneth M. Peters
    • 2
    Email author
  1. 1.Female Pelvic Medicine and Reconstructive SurgeryBeaumont Health SystemRoyal OakUSA
  2. 2.Female Pelvic Medicine and Reconstructive Surgery, Beaumont Health SystemOakland University William Beaumont School of MedicineRoyal OakUSA

Personalised recommendations